

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 February 2019 (14.02.2019)



(10) International Publication Number
WO 2019/032662 A1

(51) International Patent Classification:

C12Q 1/68 (2018.01) A61K 39/00 (2006.01)
G01N 33/573 (2006.01) A61K 38/21 (2006.01)
G01N 33/574 (2006.01) A61K 39/395 (2006.01)
G01N 33/68 (2006.01) A61K 47/48 (2006.01)

(21) International Application Number:

PCT/US2018/045742

(22) International Filing Date:

08 August 2018 (08.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/542,944 09 August 2017 (09.08.2017) US

(71) Applicants: **ORIONIS BIOSCIENCES INC.** [US/US];
275 Grove Street, Newton, MA 02466 (US). **ORIONIS
BIOSCIENCES NV.** [BE/BE]; Rijvisschestraat 120,
B-9052 Zwinjnaarde (BE).

(72) Inventors: **KLEY, Nikolai**; c/o Orionis Biosciences Inc.,
275 Grove Street, Newton, MA 02466 (US). **TAV-
ERNIER, Jan**; Bottelweg 2, B-9860 Balegem (BE). **ZABEAU,
Lenart**; c/o Orionis Biosciences NV., Rijvisschestraat 120,
B-9052 Zwinjnaarde (BE). **DEPLA, Erik**;
c/o Orionis Biosciences NV., Rijvisschestraat 120, B-9052
Zwinjnaarde (BE).

(74) Agent: **ALTIERI, Stephen L.** et al.; Morgan, Lewis &
Bockius, LLP, 1111 Pennsylvania Avenue, NW, Washing-
ton, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CLEC9A BINDING AGENTS AND USE THEREOF

(57) Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.

Figure 7B



WO 2019/032662 A1